Cytochroma Inc. announces completion of $3 million raise



    MARKHAM, ON, March 29 /CNW/ - Cytochroma announced today that it has
secured $3 million in new funding from the Canadian Medical Discoveries Fund
Inc. (CMDF) and University Medical Discoveries Inc. (UMDI). This new funding
will help support two ongoing clinical trials, a Phase I trial for secondary
hyperparathyroidism and a Phase II trial in chronic plaque psoriasis as well
as the initiation of two other clinical programs in 2007.
    Cytochroma recently initiated a Phase I clinical trial of CTA018
Injection under development for the treatment of secondary hyperparathyroidism
in chronic kidney disease patients. This trial is an open label,
placebo-controlled, randomized study of CTA018 administered intravenously to
20 healthy volunteers. The goal of the trial is to evaluate the safety of
single doses of CTA018 Injection up to a high dose of 180 micro g. Two dose
levels of CTA018, one being the maximum tolerated dose, will be further
evaluated during repeated administration in a continuation of this safety
study set to begin in April 2007. Final results for the clinical trial are
expected in July 2007.
    Cytochroma recently completed enrollment in a Phase II trial of CTA018
Cream as a new treatment for chronic plaque psoriasis. The trial, which is on
schedule for completion in May 2007, is a randomized, double-blind, placebo
controlled study being conducted in 16 clinics across the United States with a
total of 147 subjects. Final results from this trial will be available in July
2007.
    "We are excited about the recent progress made by Cytochroma in bringing
products to the clinic, and we are pleased to continue our support of
Cytochroma's promising pipeline of clinical candidates," stated Dr. Michael
Cross, Senior Vice President, Jove Investment Management Inc., manager of CMDF
and UMDI.
    "Cytochroma is right on track to achieving the key business milestones
that we have targeted for 2007," stated Mr. Eric Messner, Vice President,
Commercial Operations. "This new funding is in addition to the recent $21 M
financing announced by Cytochroma in January of this year."

    About Cytochroma Inc.

    Cytochroma (www.cytochroma.com) is an integrated specialty pharmaceutical
company engaged in the development and commercialization of proprietary
products to treat and prevent the clinical consequences of diseases and
disorders related to vitamin D deficiency and chronic kidney disease (CKD).
The Company has an advanced portfolio of new products targeting vitamin D
deficiency and secondary hyperparathyroidism in patients with moderate to
severe CKD and end-stage renal disease. In addition, the Company has a
psoriasis candidate in Phase II clinical development and is developing a
portfolio of candidates to address hyperphosphatemia in CKD including novel
antibody products. Cytochroma is a privately held company with offices in
Markham, Ontario.




For further information:

For further information: Eric J. Messner, Vice President, Commercial
Operations, (905) 479-5306 ext. 338, eric.messner@cytochroma.com

Organization Profile

Cytochroma

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890